TABLE 1.
Patient characteristics
| Patients with TKI‐induced hypertension (N = 27) | Patients without TKI‐induced hypertension (N = 25) | |
|---|---|---|
| Median age (years) | 61.6 | 60.8 |
| Male: female | 24:3 | 18:7 |
| History of nephrectomy | 19 (70%) | 10 (40%) |
| Histology | ||
| Clear cell | 25 (93%) | 24 (96%) |
| Other | 2 (7%) | 1 (4%) |
| Type of TKI | ||
| Sunitinib | 11 (41%) | 14 (56%) |
| Pazopanib | 14 (52%) | 11 (44%) |
| Sorafenib | 1 (4%) | 0 |
| Cabozantinib | 1 (4%) | 0 |
| Axitinib | 0 | 0 |
| Stable HTN at baseline | 9 (33%) | 8 (32%) |
| TKI‐induced hypertension | ||
| Grade 2 | 19 (70%) | NA |
| Grade 3 | 8 (30%) | NA |
| TKI dose reduced/stopped due to HTN | 7 (26%) | NA |
| Antihypertensive commenced | 22 (82%) | NA |
| Other adverse‐events | ||
| Diarrhea | 7 (26%) | 5 (20%) |
| Hand‐foot syndrome | 2 (7%) | 5 (20%) |
| Mucositis | 3 (11%) | 1 (4%) |
| Abnormal blood | 1 (4%) | 1 (4%) |
| Other | 6 (22%) | 3 (12%) |
| Treatment response | ||
| Partial | 12 (44%) | 3 (12%) |
| Stable | 9 (33%) | 13 (52%) |
| Progression | 4 (15%) | 7 (28%) |
| Median PFS (weeks) | 30.46 | 22.22 |
| 6‐month survival | 22 (82%) | 19 (76%) |
| 12‐month survival | 15 (56%) | 11 (44%) |
Abbreviations: HTN, hypertension, NA, not applicable, PFS, progression‐free survival, TKI, tyrosine‐kinase inhibitor.